AI summary · may contain errors
Single-cell RNA–ATAC profiling of Ewing sarcoma identifies multiple fusion-regulated gene regulatory modules, with their prevalence varying across cell lines and within patient tumors.
- Open access
Moving in Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, medRxiv, Molecular Cancer Therapeutics, bioRxiv, Cancer Discovery and Frontiers in Genetics.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Single-cell RNA–ATAC profiling of Ewing sarcoma identifies multiple fusion-regulated gene regulatory modules, with their prevalence varying across cell lines and within patient tumors.
AI summary · may contain errors
ATRX protein loss is linked to significantly worse outcomes in uterine leiomyosarcoma (53%), undifferentiated pleomorphic sarcoma (37%), and dedifferentiated liposarcoma (8%).
AI summary · may contain errors
Programmable non-viral delivery of dCas9-KRAB RNPs silences the oncogenic fusion EWSR1-FLI1 in Ewing sarcoma, producing potent anti-tumor effects in xenografts and EWS-related PDXs.
AI summary · may contain errors
In 347 patients with Ewing sarcoma across Euro Ewing 2012 (EE2012) phase II/III, ctDNA-detected TP53/STAG2 loss-of-function or CDKN2A focal deletions defined a molecular high-risk subgroup with worse survival (EFS HR 3.6, OS HR 4.3).
AI summary · may contain errors
Stress- and hypoxia-associated dedifferentiation programs are selectively enriched in paediatric B choroid plexus tumours and correlate with poorer survival.
AI summary · may contain errors
CDK8 inhibitors, including a novel pyridyl imidazole, impair the EWSR1::FLI1 transcriptional program in Ewing sarcoma cells by inducing Mediator trapping on chromatin.
AI summary · may contain errors
CDK8 inhibition releases the muscle differentiation block in fusion-driven alveolar rhabdomyosarcoma, impairing tumor growth and inducing myogenic differentiation in vitro and in vivo.
AI summary · may contain errors
Dual LAG-3/PD-1 blockade with IBI110 plus sintilimab in advanced alveolar soft part sarcoma achieved an overall response rate of 51.8% (14/27).
AI summary · may contain errors
JNK activation sustains CDC73 stability in osteosarcoma by antagonizing UBR5-mediated CDC73 polyubiquitination, with Lys257 identified as the key ubiquitination residue.
AI summary · may contain errors
Combination chromatin-directed inhibition with tazemetostat plus entinostat enhances GD2 expression and enables long-term tumor control by GD2.CAR T cells in xenograft models of Ewing sarcoma and osteosarcoma.
AI summary · may contain errors
In 2023, global malignant bone cancer burden included 111 000 cases, 76 600 deaths, and 3.02 million DALYs, with age-specific peaks and regional ASR disparities.
AI summary · may contain errors
Risvutatug rezetecan improved BICR-assessed progression-free survival versus gemcitabine-docetaxel in Chinese patients with relapsed or refractory osteosarcoma, with median 5.5 vs 1.4 months (HR 0.33).
AI summary · may contain errors
In 3,569 sarcoma cases versus 21,788 controls, no novel sarcoma susceptibility genes were identified despite exome-wide testing of rare deleterious variants.
AI summary · may contain errors
Personalized ctDNA profiling in 106 patients with high-risk localized soft tissue sarcoma detected baseline ctDNA in 85% and tracked perioperative changes linked to survival.
AI summary · may contain errors
In primary osteosarcoma single-cell RNA-seq (GSE162454; six patients), myeloid cells (34.0%) and osteoblasts (16.6%) show distinct inflammatory versus osteogenic programs, with strongest ligand-receptor scores including MIF-CD74.
AI summary · may contain errors
MSI-high is rare in sarcomas (<1%), but in a clinically sequenced cohort it concentrates in pleomorphic and radiation-associated subtypes, including PRMS (36%).
AI summary · may contain errors
In 31 patients with advanced sarcoma receiving MASCT-I maintenance after first-line chemotherapy, median PFS1 was 9.5 months and median OS was 33.8 months after 63.6 months follow-up.
AI summary · may contain errors
Brigimadlin demonstrates clear biological activity in dedifferentiated liposarcoma, with median PFS of 8.4 months and an objective response rate of 22.3%.
AI summary · may contain errors
In first-line MDM2-amplified locally advanced/metastatic dedifferentiated liposarcoma, brigimadlin did not meet the progression-free survival endpoint versus doxorubicin (8.4 vs 7.2 months; HR 0.79; P=0.096).
AI summary · may contain errors
Concurrent neoadjuvant epirubicin/ifosfamide with preoperative radiotherapy in high-risk soft-tissue sarcoma is feasible, with similar hematologic toxicity and a higher RECIST response (20.3% vs 9.8%).
AI summary · may contain errors
Region-based DNA methylation models enable individualized risk prognostication and treatment response prediction at osteosarcoma diagnosis, with prognostic effects independent of known confounders.
AI summary · may contain errors
A five-miRNA Index 5 derived from TCGA-SARC sarcoma microRNA profiles achieves AUC 0.93 in training and 0.97 on external GSE36982 data.
AI summary · may contain errors
In 301 patients with FDG-avid rhabdomyosarcoma, PET detected bone marrow metastases with 98% sensitivity and 90% specificity versus BMAB, enabling omission when PET is negative.
AI summary · may contain errors
Alectinib produced a centrally confirmed objective response rate of 43.8% in Cohort A (n=16) of patients with advanced ALK-altered solid tumors.
Journals this month
Topics moving, week to 17 Nov 2026
By field